CPhI, the annual pharmaceutical chemicals trade show, held last week in Frankfurt, brought out the usual selection of companies looking for customers and partners. Northern Ireland’s Almac announced a partnership with Novozymes to conjugate albumin-based proteins to peptides and small-molecule drugs to improve therapeutic half-life and targeting. The collaboration combines Novozymes’s Recombumin Flex technology with Almac’s protein conjugation capabilities. SAFC, the custom manufacturing arm of Sigma-Aldrich, has joined with catalysis developer CatSci, a 2010 AstraZeneca spin-off, to increase access to synthesis technologies. Meanwhile, Paris-based Axyntis has joined with Fuji Silysia Chemical, a Japanese silica chemistry specialist, to acquire Kyralia, a French chromatography services firm. To be renamed Kyrapharm, the operation will move to Axyntis’s site in Pithiviers, France. Separately, Albemarle said it will open a kilogram-scale lab at its pharmaceutical chemicals facility in South Haven, Mich., early next year. The lab will allow Albemarle to handle customer projects from clinical development through commercial production.